US FDA explains drug label comprehension studies
This article was originally published in SRA
The US Food and Drug Administration has issued guidance explaining how sponsors of non-prescription medicines should design label comprehension studies for assessing the extent to which consumers understand the information on a drug label1,2.The guidance deals with the general concepts that should be considered in the design and conduct of such studies.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.